- 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS
-
Compounds of formula (I) wherein Het1, Het2, R1, R2 and R3 are as defined in the description. Medicaments.
- -
-
Page/Page column 140-141
(2021/02/05)
-
- Substituted pyridazinone compound and application thereof
-
The invention provides a substituted pyridazinone compound and application thereof. The substituted pyridazinone compound is a compound shown in a general formula I, or a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvent compound, a poly
- -
-
Paragraph 0086-0090
(2021/04/14)
-
- Pyridazinone derivative and application thereof
-
The invention provides a pyridazinone derivative and an application thereof, the pyridazinone derivative with the structure shown in the formula (I) provided by the invention has good activity as a thyroid hormone beta receptor agonist by selecting a specific modification group. The compound can be used for treating and/or preventing diseases caused by thyroid hormone regulation.
- -
-
Paragraph 0074-0079
(2020/11/23)
-
- THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS
-
Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
- -
-
Paragraph 0366-0367
(2020/05/02)
-
- MODULATORS OF THR-β AND METHODS OF USE THEREOF
-
Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IlIa, lIIb, IlIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.
- -
-
Paragraph 00262
(2020/11/23)
-
- THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS
-
Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
- -
-
Paragraph 0304
(2020/03/09)
-
- RAD51 INHIBITORS
-
This application is directed to inhibitors of RAD51 represented by the following structural formula, (I), and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
- -
-
Page/Page column 238-239
(2020/09/27)
-
- Substituted pyridazinone compound
-
The invention provides a pharmaceutical composition of a substituted pyridazinone compound, and application thereof. The substituted pyridazinone compound is a compound as shown in formula (I), or a pharmaceutically acceptable salt, prodrug, hydrate or solvent compound, crystalline form, stereoisomer or isotopic variant thereof. The compound, namely a THR-beta agonist, can be used for treating and/or preventing diseases regulated by thyroid hormone analogs.
- -
-
Paragraph 0195; 0198
(2019/04/17)
-
- Ligand-Accelerated Iron Photocatalysis Enabling Decarboxylative Alkylation of Heteroarenes
-
A mild, practical protocol for the decarboxylative alkylation of heteroarenes has been accomplished via iron photocatalysis. A diverse range of carboxylic acids readily undergo oxidative decarboxylation and then couple with a broad array of heteroarenes in this transformation. The photoexcited state lifetimes of iron complexes are typically much shorter than those of iridium and ruthenium complexes. Here we describe our effort on iron photocatalysis by utilizing the intramolecular charge transfer pathway of iron-carboxylate complexes.
- Li, Zhenlong,Wang, Xiaofei,Xia, Siqi,Jin, Jian
-
supporting information
(2019/06/13)
-
- THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF
-
Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.
- -
-
Paragraph 00311
(2020/01/08)
-
- Unprotected Amino Acids as Stable Radical Precursors for Heterocycle C-H Functionalization
-
An efficient and general method for the C-H alkylation of heteroarenes using unprotected amino acids as stable alkyl radical precursors is reported. This one-pot procedure is performed open to air under aqueous conditions and is effective for several natural and unnatural amino acids. Heterocycles of varying structure are suitably functionalized, and reactivity trends reflect the nucleophilic character of the radical species generated.
- Mai, Duy N.,Baxter, Ryan D.
-
supporting information
p. 3738 - 3741
(2016/08/16)
-
- NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF
-
A compound represented by Formula [1] (in the formula, Z1 represents N, CH, or the like; X1 represents NH or the like; R1 represents a heteroaryl group or the like; each of R2, R3, and R4 represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R5 represents a heteroaryl group or the like) or salt thereof.
- -
-
Paragraph 0493; 0494; 0495
(2015/11/30)
-
- TRIAZOLO COMPOUNDS
-
The present invention relates to compounds of formula (I) and its use for the treatment of neurological disorders.
- -
-
Page/Page column 68
(2014/05/24)
-
- DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS
-
The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
- -
-
Page/Page column 52; 109
(2013/04/13)
-
- TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS
-
The invention relates to novel compounds of formula I where X, A?, Q1, Q2 Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated recepto
- -
-
Page/Page column 35
(2011/02/26)
-
- PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS
-
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.
- -
-
Page/Page column 63-64
(2008/06/13)
-
- Fungicidal pyridazines
-
Plants are protected from the damaging effects of Phycomycetous fungi by a series of pyridazines of formula STR1 wherein R3 is chloro, bromo, methyl, cyano or iodo; R is chloro, bromo, iodo, methyl, cyano or furan-2-ylmethoxy; R1 is
- -
-
-
- Preparation of substituted pyridazines
-
A novel process is described for preparing substituted pyridazines, where a less substituted pyridazine is reacted with a carboxylic acid in the presence of a silver ion as catalyst, using peroxydisulfate ion. The reaction is run at a temperature from about 40° to 80° C. in an aqueous solvent system and mineral acid. The substituted pyridazines are useful as intermediates to herbicidal and fungicidal compounds.
- -
-
-